Re Argentina, Israel, and Australia which they havent taken up the options for
The second is with Teva Pharmaceuticals for Brazil, Chile and Mexico. Teva has alreadylodged its marketing approval in Chile and is working closely with the SUDA team toprogress the application in the large market of Brazil. Teva is continuing to evaluate theMexican market. Teva had an option on the territories of Argentina, Israel and Australiabut has decided not to exercise it. SUDA has a number of potential partners for theseregions and will reinvigorate discussions in these markets.
SUD Price at posting:
0.5¢ Sentiment: Hold Disclosure: Held